Cara Therapeutic is a biotechnology business based in the US. Cara Therapeutic shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.27 – an increase of 4.16% over the previous week. Cara Therapeutic employs 55 staff and has a trailing 12-month revenue of around $11 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.27 |
|---|---|
| 52-week range | $0.24 - $1.40 |
| 50-day moving average | $0.30 |
| 200-day moving average | $0.55 |
| Wall St. target price | $1.01 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2651 from 2024-10-18
| 1 week (2024-10-15) | 3.96% |
|---|---|
| 1 month (2024-09-20) | -12.22% |
| 3 months (2024-07-22) | -28.04% |
| 6 months (2024-04-22) | -63.70% |
| 1 year (2023-10-20) | -79.45% |
|---|---|
| 2 years (2022-10-21) | -97.27% |
| 3 years (2021-10-22) | 12.7 |
| 5 years (2019-10-22) | 19.33 |
| Revenue TTM | $11 million |
|---|---|
| Gross profit TTM | $-56,141,000 |
| Return on assets TTM | -63.43% |
| Return on equity TTM | -184.32% |
| Profit margin | 0% |
| Book value | $0.21 |
| Market Capitalization | $14.5 million |
TTM: trailing 12 months
We're not expecting Cara Therapeutic to pay a dividend over the next 12 months.
Cara Therapeutic's shares were split on a 1:2 basis on 15 January 2014 . So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutic shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutic shares which in turn could have impacted Cara Therapeutic's share price.
Over the last 12 months, Cara Therapeutic's shares have ranged in value from as little as $0.24 up to $1.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutic's is 0.699. This would suggest that Cara Therapeutic's shares are less volatile than average (for this exchange).
Cara Therapeutics, Inc. , a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co. , Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.